What is Leerink Partnrs’ Estimate for KYTX FY2029 Earnings?

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) – Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for shares of Kyverna Therapeutics in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith anticipates that the company will post earnings per share of ($4.19) for the year. The consensus estimate for Kyverna Therapeutics’ current full-year earnings is ($3.29) per share.

KYTX has been the topic of several other research reports. HC Wainwright reduced their price target on shares of Kyverna Therapeutics from $7.00 to $6.00 and set a “neutral” rating on the stock in a report on Wednesday, November 20th. UBS Group started coverage on Kyverna Therapeutics in a research note on Thursday, October 10th. They issued a “buy” rating and a $13.00 target price on the stock. Finally, Wells Fargo & Company dropped their price target on Kyverna Therapeutics from $44.00 to $24.00 and set an “overweight” rating for the company in a research report on Friday, November 15th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $25.71.

Kyverna Therapeutics Price Performance

Shares of NASDAQ KYTX opened at $3.11 on Friday. The company’s 50-day moving average price is $3.96 and its 200 day moving average price is $5.47. Kyverna Therapeutics has a 52 week low of $3.02 and a 52 week high of $35.06.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its earnings results on Wednesday, November 13th. The company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.01. The firm had revenue of $0.01 million during the quarter.

Institutional Investors Weigh In On Kyverna Therapeutics

Several hedge funds have recently made changes to their positions in KYTX. Millennium Management LLC increased its stake in Kyverna Therapeutics by 32.8% in the second quarter. Millennium Management LLC now owns 923,082 shares of the company’s stock valued at $6,923,000 after purchasing an additional 227,988 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Kyverna Therapeutics by 32.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 37,794 shares of the company’s stock worth $283,000 after acquiring an additional 9,300 shares during the period. Creative Planning purchased a new position in shares of Kyverna Therapeutics during the 3rd quarter worth about $54,000. Novo Holdings A S boosted its position in shares of Kyverna Therapeutics by 5.7% in the third quarter. Novo Holdings A S now owns 1,850,000 shares of the company’s stock worth $9,046,000 after acquiring an additional 100,000 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in Kyverna Therapeutics by 33.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 166,635 shares of the company’s stock valued at $815,000 after purchasing an additional 41,558 shares during the period. Institutional investors and hedge funds own 18.08% of the company’s stock.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.